Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! Registry

BACKGROUND/AIMS: To describe baseline characteristics and 12-month outcomes with vascular endothelial growth factor (VEGF) inhibitors of treatment-naïve hemiretinal vein occlusion (HRVO) compared with branch (BRVO) and central (CRVO) variants in routine clinical care. METHODS: A database observation...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunt, Adrian Robert, Nguyen, Vuong, Arnold, Jennifer J, McAllister, Ian L, Mehta, Hemal, Invernizzi, Alessandro, Ponsioen, Theodorus, Gabrielle, Pierre-Henry, O'Toole, Louise, Kusenda, Pavol, Alforja, Socorro, Barthelmes, Daniel, Gillies, Mark C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314087/
https://www.ncbi.nlm.nih.gov/pubmed/35078771
http://dx.doi.org/10.1136/bjophthalmol-2021-320482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314087/
https://www.ncbi.nlm.nih.gov/pubmed/35078771
http://dx.doi.org/10.1136/bjophthalmol-2021-320482

Ejemplares similares